The previous studies have demonstrated that lymphocyte GRK2 protein levels can independently predict prognosis in patients with HF [112]; cardiac GRK2 is a candidate treatment target in gene therapy in HF [113] and GRK2 regulates complex signaling pathways leading to fibrosis [114], which is highly prevalent in HF. The gene discussed is GRK2; the disease is hydrops fetalis.